135575-42-7

Basic information

• Product Name: Pneumocandin B0
• Synonyms: Pneumocardin B0;pneumocandin B(0);B0 PneuMocandin B0;Caspofungin PneuMocandin B0 IMpurity;Caspofungin Intermediate;neumocandin B0;CFA;PneumocandinBo
• CAS NO: 135575-42-7
• Molecular Formula: C₅₀H₈₀N₈O₁₇
• Molecular Weight: 1065.22
• EINECS: 1312995-182-4
• Product Categories: Antifungals;Chiral Reagents;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals;API;Other APIs
• Mol File: 135575-42-7.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 1442.936 °C at 760 mmHg
• Flash Point: 826.458 °C
• Appearance: /
• Density: 1.411 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.629
• Storage Temp.: Sealed in dry,Store in freezer, under -20°C
• Solubility: DMSO (Slightly), Methanol (Sparingly)
• PKA: 9.86±0.26(Predicted)
• CAS DataBase Reference: Pneumocandin B0(CAS DataBase Reference)
• NIST Chemistry Reference: Pneumocandin B0(135575-42-7)
• EPA Substance Registry System: Pneumocandin B0(135575-42-7)

Safety Data

• Hazardous Substances Data: 135575-42-7(Hazardous Substances Data)

Usage

Description

Pneumocandin B0 is an antifungal lipopeptide that acts by inhibiting the synthesis of β-(1,3)-D-glucan, a component of fungal cell walls. It is the major analogue of a family of lipopeptides isolated from various species of different genera, such as Cryptosporiopsis, Glarea, and Pezicula. Pneumocandin B0 can be used to synthesize the echinocandin caspofungin acetate.

Uses

Used in Pharmaceutical Industry:
Pneumocandin B0 is used as an antifungal agent for treating infections caused by susceptible fungi. It is particularly effective against Candida and Aspergillus species, which are common causes of fungal infections in humans.
Used in Drug Synthesis:
Pneumocandin B0 is used as the starting point for the synthesis of the antifungal drug caspofungin. Caspofungin is a semi-synthetic lipopeptide that has been developed for the treatment of invasive fungal infections, particularly those caused by Candida and Aspergillus species.
Used in Research and Development:
Pneumocandin B0 serves as a valuable compound in the research and development of new antifungal agents. Its unique mechanism of action and potent antifungal properties make it an important tool for studying the biology of fungal cell walls and the development of novel therapeutic strategies against fungal infections.

InChI:InChI=1/C50H80N8O17/c1-5-25(2)20-26(3)12-10-8-6-7-9-11-13-37(66)52-31-22-35(64)46(71)56-48(73)41-33(62)18-19-57(41)50(75)39(34(63)23-36(51)65)54-47(72)40(43(68)42(67)28-14-16-29(60)17-15-28)55-45(70)32-21-30(61)24-58(32)49(74)38(27(4)59)53-44(31)69/h14-17,25-27,30-35,38-43,46,59-64,67-68,71H,5-13,18-24H2,1-4H3,(H2,51,65)(H,52,66)(H,53,69)(H,54,72)(H,55,70)(H,56,73)/t25?,26?,27-,30+,31-,32-,33-,34-,35+,38-,39-,40-,41-,42-,43-,46+/m0/s1

Downstream Products

• 162808-60-8 C₅₂H₈₆N₁₀O₁₆ 
• 179463-17-3 caspofungin diacetate 

Related news

Antifungal lipopeptides: Structure-activity relationships of 3-hydroxyglutamine-modified Pneumocandin B0 (cas 135575-42-7) derivatives08/14/2019

Selective methanolysis or dehydration followed by reduction of the 3-hydroxyglutamine residue of pneumocandin B0 (1) or its dideoxy analog 5 (L-692,289) gave the methyl 3-hydroxyglutamate and 3-hydroxyornithine analogs 6 and 9, respectively. Further derivatization of these analogs allowed a stud...detailed

Relevant articles and documents

Stationary phases and a purification process using the stationary phases

This invention relates to a novel stationary phase of Formula I and a method for purifying a peptide or lipopeptide in liquid chromatography using select stationary phases, including the stationary phases of Formula I to improve the resolution and/or productivity of the purification. This chromatographic method can be used for either an analytical or preparative scale purification.